Merck & Co. (MRK) : First Allied Advisory Services reduced its stake in Merck & Co. by 4.94% during the most recent quarter end. The investment management company now holds a total of 198,001 shares of Merck & Co. which is valued at $10.7 Million after selling 10,286 shares in Merck & Co. , the firm said in a disclosure report filed with the SEC on May 12, 2016.Merck & Co. makes up approximately 0.60% of First Allied Advisory Services’s portfolio.
Other Hedge Funds, Including , Tredje Ap-fonden boosted its stake in MRK in the latest quarter, The investment management firm added 88,545 additional shares and now holds a total of 452,610 shares of Merck & Co. which is valued at $24.4 Million. Merck & Co. makes up approx 1.13% of Tredje Ap-fonden’s portfolio.Brown Advisory Securities reduced its stake in MRK by selling 1,990 shares or 2.76% in the most recent quarter. The Hedge Fund company now holds 70,095 shares of MRK which is valued at $3.8 Million. Merck & Co. makes up approx 1.25% of Brown Advisory Securities’s portfolio.Neuberger Berman Group boosted its stake in MRK in the latest quarter, The investment management firm added 919,522 additional shares and now holds a total of 1,486,923 shares of Merck & Co. which is valued at $79.7 Million. Merck & Co. makes up approx 0.11% of Neuberger Berman Group’s portfolio.Calvert Investment Management reduced its stake in MRK by selling 1,780 shares or 0.34% in the most recent quarter. The Hedge Fund company now holds 523,298 shares of MRK which is valued at $28 Million. Merck & Co. makes up approx 1.24% of Calvert Investment Management’s portfolio. Buffington Mohr Mcneal added MRK to its portfolio by purchasing 4,200 company shares during the most recent quarter which is valued at $230,328. Merck & Co. makes up approx 0.10% of Buffington Mohr Mcneal’s portfolio.
Merck & Co. opened for trading at $54.83 and hit $55.54 on the upside on Friday, eventually ending the session at $55.11, with a gain of 0.97% or 0.53 points. The heightened volatility saw the trading volume jump to 86,33,110 shares. Company has a market cap of $152,546 M.
On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.
Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.